Short-Term Debt to Capital: caredx.com (CDNA)

Brandmark of CareDx Inc (CDNA)

CareDx, Inc (CDNA) is currently undergoing a cyclical upturn, recovering profits due to the critical importance of diagnostic procedures. High cash flow resilience is driven by patients' lifelong need for monitoring, which fixes the indicator at 0.02. This price action reflects the efficiency of a model where core tests are performed in-house while ancillary services are outsourced.

CDNA - CareDx Short-Term Debt to Capital over the range 07/04/2022 - 10/31/2026

Analytical breakdowns for CareDx, Inc

- stock quotes and analyst forecast:
Stock Price CareDx, Inc.|CDNA - Average Forecast Price
- company stock exchange capitalization indicators:
Market Capitalization CareDx Inc|CDNA - Business Value
- book capitalization information:
Book Value per Share CareDx|CDNA - Book Capitalization|Market Value to Book Value Ratio caredx.com|CDNA - Total Business Assets
- business debt structure and liquidity details:
Total Debt to Capital CareDx, Inc|CDNA - Long-Term Debt to Capital|Short-Term Debt to Equity CareDx Health|CDNA - Company Debts|Debt to Book Value CareDx Inc|CDNA - Long-Term Debt|Company Short-Term Debt CareDx|Quick Ratio caredx.com
- earnings and market ratios statistics:
CDNA - Net Financial Result
General company analysis:caredx.com CDNA
Brand item of CareDx Health

Leveraging a unique technological advantage in transplant diagnostics, CareDx, Inc (CDNA) utilizes innovation to establish a high barrier to entry. The ratio of liabilities maturing within one year to equity measures liquidity risk and dependence on rapid refinancing; therefore, the current level of short-term capital burden serves as an indicator of the balance between financial stability and the pace of business expansion.

Competitors of CareDx, Inc (CDNA)

Short-Term Debt to Capital A|DGX - Current Liabilities to Capital|Short-Term Debt to Capital ILMN (Illumina, Inc.)|EXAS: Short-Term Debt to Capital Ratio|Revvity - Short-Term Debt to Capital|BIO - Short-Term Debt to Capital|Anbio Tech (NNNN) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio SHC|QDEL (QuidelOrtho) - Short-Term Debt to Capital|Short-Term Debt to Capital opko.com|Short-Term Debt to Equity Maravai LifeSciences Holdings, Inc. (MRVI)|Short-Term Debt to Equity FLGT (Fulgent Genetics Inc)|Fluidigm - Short-Term Debt to Equity Ratio|Cytek Corp (CTKB) - Current Liabilities to Capital|OSUR - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient Exagen Inc. XGN|MDXH: Short-Term Debt to Capital|LUCD - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Prenetics Global Limited|Insight Molecular (IMDX) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital TRIB|Short-Term Debt to Equity Ratio prophaselabs.com PRPH|Short-Term Debt to Capital AIMD (Ainos)|Short-Term Debt to Capital Co-Diagnostics Inc CODX|HSCS - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital BMRA (Biomerica Inc)|CDIO: Short-Term Debt to Capital|Current Liabilities to Capital viraxbiolabs.com (VRAX)|BJDX (Bluejay Diagnostics, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital Ratio AWH (Aspira Women's Health, Inc.)|Short-Term Debt to Equity Ratio AXDX (Accelerate Diagnostics, Inc)|Centogene - Short-Term Debt to Capital Ratio|Enzo Biochem - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital FRES|GTG Labs - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient 23andMe Holding Co ME|Psychemedics Corp (PMD) - Short-Term Debt to Equity